- Title
- Comparison between [⁶⁸Ga]Ga-PSMA-617 and [¹⁸F]FET PET as Imaging Biomarkers in Adult Recurrent Glioblastoma
- Creator
- Brighi, Caterina; Puttick, Simon; Woods, Amanda; Keall, Paul; Tooney, Paul A.; Waddington, David E. J.; Sproule, Vicki; Rose, Stephen; Fay, Michael
- Relation
- International Journal of Molecular Sciences Vol. 24, Issue 22, no. 16208
- Publisher Link
- http://dx.doi.org/10.3390/ijms242216208
- Publisher
- MDPI AG
- Resource Type
- journal article
- Date
- 2023
- Description
- The aim of this prospective clinical study was to evaluate the potential of the prostate specific membrane antigen (PSMA) targeting ligand, [68Ga]-PSMA–Glu–NH–CO–NH–Lys-2-naphthyl-L-Ala-cyclohexane-DOTA ([68Ga]Ga-PSMA-617) as a positron emission tomography (PET) imaging biomarker in recurrent glioblastoma patients. Patients underwent [68Ga]Ga-PSMA-617 and O-(2-[18F]-fluoroethyl)-L-tyrosine ([18F]FET) PET scans on two separate days. [68Ga]Ga-PSMA-617 tumour selectivity was assessed by comparing tumour volume delineation and by assessing the intra-patient correlation between tumour uptake on [68Ga]Ga-PSMA-617 and [18F]FET PET images. [68Ga]Ga-PSMA-617 tumour specificity was evaluated by comparing its tumour-to-brain ratio (TBR) with [18F]FET TBR and its tumour volume with the magnetic resonance imaging (MRI) contrast-enhancing (CE) tumour volume. Ten patients were recruited in this study. [68Ga]Ga-PSMA-617-avid tumour volume was larger than the [18F]FET tumour volume (p = 0.063). There was a positive intra-patient correlation (median Pearson r = 0.51; p < 0.0001) between [68Ga]Ga-PSMA-617 and [18F]FET in the tumour volume. [68Ga]Ga-PSMA-617 had significantly higher TBR (p = 0.002) than [18F]FET. The [68Ga]Ga-PSMA-617-avid tumour volume was larger than the CE tumour volume (p = 0.0039). Overall, accumulation of [68Ga]-Ga-PSMA-617 beyond [18F]FET-avid tumour regions suggests the presence of neoangiogenesis in tumour regions that are not overly metabolically active yet. Higher tumour specificity suggests that [68Ga]-Ga-PSMA-617 could be a better imaging biomarker for recurrent tumour delineation and secondary treatment planning than [18F]FET and CE MRI.
- Subject
- [⁶⁸Ga]Ga-PSMA-617; recurrent glioblastoma; positron emission tomography imaging of glioblastoma; theranostics for glioblastoma
- Identifier
- http://hdl.handle.net/1959.13/1501090
- Identifier
- uon:55074
- Identifier
- ISSN:1422-0067
- Rights
- © 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
- Language
- eng
- Full Text
- Reviewed
- Hits: 596
- Visitors: 635
- Downloads: 44
| Thumbnail | File | Description | Size | Format | |||
|---|---|---|---|---|---|---|---|
| View Details Download | ATTACHMENT02 | Publisher version (open access) | 3 MB | Adobe Acrobat PDF | View Details Download |